--- title: "Aura Biosciences (AURA) news: offering and buyback" url: "https://aibio.space/companies/aura-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AURA offering and buyback news: Aura Biosciences agrees to repurchase Matrix Capital's 6,922,870 shares at $5.64 offering price. Aura Biosciences, Inc." --- AURA Aura Biosciences, Inc. NASDAQ · United States # Aura Biosciences (AURA) news AURA offering and buyback news Distress · 2026-08-11 ## [Aura Biosciences cuts about 20% of workforce, expects cash runway into 2029](https://aibio.space/news/aura-biosciences-cuts-about-20-percent-workforce-expects-cash-runway/) The company is refocusing on ocular oncology and minimizing resources for its bladder cancer program. Its Phase 3 CoMpass trial is fully enrolled with 108 patients. ## Latest Aura Biosciences news 1. 2026-08-05 Listings [Aura Biosciences holders approve raising authorized shares to 500,000,000](https://aibio.space/news/aura-biosciences-holders-approve-raising-authorized-shares-500-000-000/) Authorized common shares rise from 150,000,000. The August 5, 2026 special meeting also approved an amendment to the 2021 Stock Option and Incentive Plan. 2. 2026-05-04 Mergers [Aura Biosciences agrees to repurchase Matrix Capital's 6,922,870 shares at $5.64 offering price](https://aibio.space/news/aura-biosciences-agrees-repurchase-matrix-capitals-6-922-870-shares-5/) Aura Biosciences agreed to buy back up to 6,922,870 shares from Matrix Capital at $5.64, the price of an equity offering it announced on May 4, 2026. The buyback comes out of the offering's proceeds, and the company put preliminary cash at $114.7 million as of March 31, 2026. ## Aura Biosciences at a glance - **Ticker**: AURA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $67.8 million ### Related companies - [Axsome Therapeutics](https://aibio.space/companies/axsome-therapeutics/) NASDAQ: AXSM - [Precision BioSciences](https://aibio.space/companies/precision-biosciences/) NASDAQ: DTIL - [NANOLOGIX INC](https://aibio.space/companies/nanologix/) OTC: NNLX - [Arrowhead Pharmaceuticals](https://aibio.space/companies/arrowhead-pharmaceuticals/) NASDAQ: ARWR - [Altimmune](https://aibio.space/companies/altimmune/) NASDAQ: ALT - [IN8bio](https://aibio.space/companies/in8bio/) NASDAQ: INAB - [Phio Pharmaceuticals](https://aibio.space/companies/phio-pharmaceuticals/) NASDAQ: PHIO - [SORRENTO THERAPEUTICS INC](https://aibio.space/companies/sorrento-therapeutics/) OTC: SRNE ### Also on NASDAQ - [Neurocrine Biosciences](https://aibio.space/companies/neurocrine-biosciences/) NBIX - [SNDL](https://aibio.space/companies/sndl/) SNDL - [Medline](https://aibio.space/companies/medline/) MDLN - [Fulgent Genetics](https://aibio.space/companies/fulgent-genetics/) FLGT - [Inhibikase Therapeutics](https://aibio.space/companies/inhibikase-therapeutics/) IKT - [Fortress Biotech](https://aibio.space/companies/fortress-biotech/) FBIO ## Aura Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$90.3 million](https://www.sec.gov/Archives/edgar/data/1501796/000119312526130401/) | [$73.3 million](https://www.sec.gov/Archives/edgar/data/1501796/000119312526130401/) | | Net income (loss) | [-$106.2 million](https://www.sec.gov/Archives/edgar/data/1501796/000119312526130401/) | [-$86.9 million](https://www.sec.gov/Archives/edgar/data/1501796/000119312526130401/) | | Cash from operations | [-$84.7 million](https://www.sec.gov/Archives/edgar/data/1501796/000119312526130401/) | [-$79.8 million](https://www.sec.gov/Archives/edgar/data/1501796/000119312526130401/) | | Cash and equivalents | [$59.5 million](https://www.sec.gov/Archives/edgar/data/1501796/000119312526343429/) | [$31.7 million](https://www.sec.gov/Archives/edgar/data/1501796/000119312526130401/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $67.8 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Aura Biosciences Has Aura Biosciences raised money recently? Our latest story on this, dated May 4, 2026: "Aura Biosciences agrees to repurchase Matrix Capital's 6,922,870 shares at $5.64 offering price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aura-biosciences-agrees-repurchase-matrix-capitals-6-922-870-shares-5/). Does Aura Biosciences have a share buyback? Our latest story on this, dated May 4, 2026: "Aura Biosciences agrees to repurchase Matrix Capital's 6,922,870 shares at $5.64 offering price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aura-biosciences-agrees-repurchase-matrix-capitals-6-922-870-shares-5/). What is the ticker symbol of Aura Biosciences? Aura Biosciences, Inc. trades under the ticker AURA on NASDAQ. Where is Aura Biosciences listed? Aura Biosciences, Inc. is listed on NASDAQ. What is the SEC CIK of Aura Biosciences? The SEC Central Index Key (CIK) for Aura Biosciences, Inc. is 1501796. Its filings are on SEC EDGAR. How many shares does Aura Biosciences have outstanding? 103,704,809 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Aura Biosciences listed under? Our directory records Aura Biosciences, Inc. under United States. What does Aura Biosciences do? Our directory classifies Aura Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Aura Biosciences? The ISIN recorded for Aura Biosciences, Inc. is US05153U1079. Does aibio.space cover Aura Biosciences? aibio.space lists Aura Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Aura Biosciences incorporated? SEC records list its state or country of incorporation as DE. Is Aura Biosciences profitable? Aura Biosciences, Inc. reported a net loss of $106.2 million for the fiscal year ended Dec 31, 2025, and used $84.7 million of cash in operations, per its annual report to the SEC. How much does Aura Biosciences spend on research and development? $90.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Aura Biosciences have? $67.8 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Aura Biosciences (AURA) stock news? Our latest story on Aura Biosciences, dated Aug 11, 2026: "Aura Biosciences cuts about 20% of workforce, expects cash runway into 2029". The company is refocusing on ocular oncology and minimizing resources for its bladder cancer program. Its Phase 3 CoMpass trial is fully enrolled with 108 patients. [Source](https://aibio.space/news/aura-biosciences-cuts-about-20-percent-workforce-expects-cash-runway/). ## Investor discussion: Aura Biosciences Members talk about Aura Biosciences (AURA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Aura Biosciences, newest first. Each line links the filing it comes from. 1. 2026-08-11 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1501796/000119312526343408/aura-ex99_1.htm) 2. 2026-08-11 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1501796/000119312526344699/d140546ds3.htm) 3. 2026-08-05 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1501796/000119312526335157/aura-20260805.htm) 4. 2026-03-30 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1501796/000119312526130401/aura-20251231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AURA on TradingView](https://www.tradingview.com/symbols/NASDAQ-AURA/). ## SEC filings and registration - **SEC name**: Aura Biosciences, Inc. - **CIK**: 1501796 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: AURA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company
Emerging growth company - **Business address**: 80 GUEST STREET, BOSTON, MA, 02135 - **Phone**: (617)500-8864 - **Shares outstanding**: 103,704,809 as of 2026-08-06 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [S-3](https://www.sec.gov/Archives/edgar/data/1501796/000119312526344699/d140546ds3.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1501796/000119312526343429/aura-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1501796/000119312526343408/aura-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1501796/000119312526335157/aura-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1501796/000119312526297992/aura-20260703.htm) filed 2026-07-08 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1501796/000119312526288498/aura-20260624.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1501796/000119312526267676/aura-20260611.htm) filed 2026-06-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1501796/000119312526216808/aura-20260331.htm) filed 2026-05-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001501796), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Aura Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AURA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Aura Biosciences, Inc. - **Ticker**: AURA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US05153U1079 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AURA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/aura-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Aura Biosciences (AURA) news: offering and buyback", 2026-10-31, https://aibio.space/companies/aura-biosciences/